> 700            original publications (peer reviewed)

> 100            overviews and textbooks articles

Publications (examples of the last 3 years)
Hirsch-Factor (Thomson and Reuter) 2020: 104

Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: another vulnerability target in Parkinson’s disease. Viewpoint. Mov Disord. 2019 October; 34(10): 1423-1429. doi: 10.1002/mds.27785.
No abstract available.
PMID:31291485

Mollenhauer B, Caspell-Garcia CJ, Coffey CS, Taylor P, Singleton A, Shaw LM, Trojanowski JQ, Frasier M, Simuni T, Iranzo A, Oertel W, Siderowf A, Weintraub D, Seibyl J, Toga AW, Tanner CM, Kieburtz K, Chahine LM, Marek K, Galasko; for the PPMI study group*. Longitudinal analyses of cerebrospinal a-synuclein in prodromal and early Parkinson’s disease.

Mov Disord. 2019 Sep;34(9):1354-1364. doi: 10.1002/mds.27806. Jul 30

PMID:31361367

Levin J, Maaß S, Schuberth M, Giese A, Oertel WH, Poewe W, Trenkwalder C, Wenning GK, Mansmann U, Südmeyer M, Eggert K, Mollenhauer B, Lipp A, Löhle M, Classen J, Münchau A, Kassubek J, Gandor F, Berg D, Egert-Schwender S, Eberhardt C, Paul F, Bötzel K, Ertl-Wagner B, Huppertz HJ, Ricard I, Höglinger GU; PROMESA Study Group. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial.

Lancet Neurol. 2019 Aug;18(8):724-735. doi: 10.1016/S1474-4422(19)30141-3.

PMID:31278067

Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA. Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?

Mov Disord. 2019 Sep 4. doi: 10.1002/mds.27823. [Epub ahead of print] Review.

PMID:31483900

Donadio V, Doppler K, Incensi A, Kuzkina A, Janzen A, Mayer G, Volkmann J, Rizzo G, Antelmi E, Plazzi G, Sommer C, Liguori R, Oertel W. Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility.

Eur J Neurol 2019 Feb 15. doi: 10.1111/ene.13939.

Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A; International REM Sleep Behavior Disorder Study Group. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.

Brain 2019 Mar 1;142(3):744-759. doi: 10.1093/brain/awz030.

Meles SK, Renken RJ, Janzen A, Mayer G, Arnaldi D, Pagani M, Morbelli S, Nobili F, Vadasz D, the REMPET study group, Leenders KL, Oertel WH. The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage Parkinson’s disease.

J Nucl Med 2018 Sep;59(9):1437-1444.

Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B, Wilmes P. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder.

Mov Disord 2018 Jan; 33(1): 88-98

Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, Reetz K, Overeem S, Pijpers A, Reesink FE, van Laar T, Teune L, Heinen L, Höffken H, Luster M, Kesper K, Leenders KL, Oertel WH. FDG-PET, dopamine transporter SPECT and olfaction: combining biomarkers in REM-sleep behavior disorder.

Mov Disord 2017; 32(10): 1482-1486

Doppler K, Jentschke H-M, Schulmeyer L, Vadasz D, Janzen A, Luster M, Höffken H, Mayer G, Brumberg J, Booij J, Musacchio T, Klebe S, Sittig-Wiegand E, Volkmann J, Sommer C, Oertel WH. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease - a clinico-pathological biomarker study.

Acta Neuropathol 2017; 133(4): 535-545

Schuepbach WMM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider G-H, Krack P, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto J-L, Bataille B, Maltete D, Damier P, Raoul S, Sixel-Döring F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Regis J-M, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G, for the EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications.
N Engl J Med 2013; 368: 610-622

Stiasny-Kolster K, Pfau DB, Oertel WH, Treede R-D, Magerl W. Hyperalgesia and functional sensory loss in restless legs syndrome.
Pain 2013; 154(8): 1457-1463

Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.
Eur J Neurol 2013; 20(1): 5-15.

Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T. Identi-fying prodromal Parkinson's disease. Pre-motor disorders in Parkinson's disease.
Mov Disord 2012; 27(5): 617-626

Oertel WH, Trenkwalder C, Benes H, Ferini-Strambi L, Högl B, Poewe W, Stiasny-Kolster K, Fichtner A, Schollmayer E, Kohnen R, García-Borreguero D; on behalf of the SP710 study group. Long-term safety and efficacy of rotigotine transdermal patch in moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.
Lancet Neurol 2011; 10(8): 710-720

Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ, Mayer G, Möller JC, Oertel WH, Knake S. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions.
Sleep 2010; 33(6): 767-773

Oertel WH, Benes H, Garcia-Borreguero D, Hoegl B, Poewe W, Montagna P, Ferini-Strambi L, Sixel-Doering F, Trenkwalder C, Partinen M, Saletu B, Polo O, Fichtner A, Schollmayer E, Kohnen R, Cassel W, Penzel T, Stiasny-Kolster K. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study.
Sleep Med 2010; 11(9): 848-856

Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Schade-Brittinger C, Oertel WH, Höglinger GU. Combined 31P- and 1H-magnetic resonance spectroscopy provides first in vivo evidence for cerebral ATP depletion in progressive supranuclear palsy
J Cereb Flow Metabol 2009; 29(4): 861-870

Oertel WH, Wolters EC, Sampaio C, Gimenez-Roldan S, Bergamesco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Mov Disord 2006; 21: 343-353

Spottke EA, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R. Cost of illness and its predictors for Parkinson's disease in Germany.
Pharmacoeconomics 2005; 23: 817-836

Stiasny-Kolster K, Doerr Y, Moeller JC, Hoeffken H, Behr TM, Oertel WH, Mayer G. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as pos-sible indicator for ?-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.
Brain 2005; 128: 126-137

Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, Hirsch EC. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy.
J Neurochem 2005; 95: 930-939

Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Noelker C, Moeller HJ, Wei X, Farlow M, Sommer N, Oertel WH. Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease.
J Neurol Neurosurg Psychiat 2004; 75:1472-1474

Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC. Dopamine depletion impairs precursor cell proliferation in Parkinson disease.
Nat Neurosci 2004; 7: 726-735

Sauer HJ, Oertel WH. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat.
Neuroscience 1994; 59: 401-416

Oertel WH, Gasser T, Ippisch R, Trenkwalder C, Poewe W. Apomorphine test for dopaminergic responsiveness.
Lancet 1989; 3: 1262-1263 (Letter)

Mugnaini E, Oertel WH. An atlas of the distribution of GABAergic neurons and terminals in the rat CNS as revealed by GAD immunohistochemistry. In: Björklund A, Hökfelt T (Eds),
Handbook of Chemical Neuroanatomy, Vol. 4, Chapter X. Elsevier, Amsterdam, North Holland, 1985; 436-608

Oertel WH, Schmechel DE, Tappaz ML, Kopin IJ. Production of a specific antiserum to rat brain glutamic acid decarboxylase by injection of an antigen-antibody complex.
Neuroscience 1981; 6: 2689-2700